CYDY News and Press, CytoDyn Inc From 06/01/21

Chiral is simultaneously working on application for Emergency Use Authorization VANCOUVER, Washington, June 01, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing VyrologixȒ...

CytoDyn's (CYDY) Brazilian distribution partner, Biomm S.A. plans to submit an authorization request to the Brazilian regulatory agency in the next few days to conduct two Phase 3 clinical trials of leronlimab in Brazil for COVID-19.The two Phase 3 trials consist of each severe and critically...

VANCOUVER, Washington, May 27, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic in...

CytoDyn (CYDY) announced the appointment of Antonio Migliarese to the position of chief financial officer of the company.Migliarese who joined CytoDyn in January 2020 previously served as the company’s vice president, corporate controller.Having started the career at Pricewaterhou...

VANCOUVER, Washington, May 20, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic in...

CytoDyn (CYDY) intends to submit the results of the completed topline report of its CD12 Phase 3 clinical trial for severe to critically ill COVID-19 patients to various regulatory agencies including India and Philippines.The results of the trial were previously shared in March...

Finalized data analysis shows CD12 trial reached almost all of its major secondary endpoints in a subpopulation (62 patients) of critically ill COVID-19 VANCOUVER, Washington, May 18, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the &#...

VANCOUVER, Washington, May 17, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic in...

CytoDyn ([[CYDY]] -26.4%) is trading sharply lower after the FDA issued a critical review of the company’s clinical trials designed to evaluate the experimental COVID-19 therapy leronlimab in COVID-19.The regulator highlights the importance of a well-designed clinical trial to assess t...

CytoDyn (CYDY) has executed an exclusive supply and distribution agreement with Macleods Pharmaceuticals in India.This commercial agreement will enable Macleods to sell leronlimab in India following regulatory clearance. “We believe there is an immediate need for leronlimab i...